1. Home
  2. CMND vs APLM Comparison

CMND vs APLM Comparison

Compare CMND & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMND
  • APLM
  • Stock Information
  • Founded
  • CMND 2017
  • APLM 2016
  • Country
  • CMND Canada
  • APLM United States
  • Employees
  • CMND N/A
  • APLM N/A
  • Industry
  • CMND Biotechnology: Pharmaceutical Preparations
  • APLM Blank Checks
  • Sector
  • CMND Health Care
  • APLM Finance
  • Exchange
  • CMND Nasdaq
  • APLM Nasdaq
  • Market Cap
  • CMND 5.3M
  • APLM 6.1M
  • IPO Year
  • CMND N/A
  • APLM N/A
  • Fundamental
  • Price
  • CMND $1.03
  • APLM $6.98
  • Analyst Decision
  • CMND
  • APLM
  • Analyst Count
  • CMND 0
  • APLM 0
  • Target Price
  • CMND N/A
  • APLM N/A
  • AVG Volume (30 Days)
  • CMND 36.4K
  • APLM 37.0K
  • Earning Date
  • CMND 09-11-2025
  • APLM 09-23-2025
  • Dividend Yield
  • CMND N/A
  • APLM N/A
  • EPS Growth
  • CMND N/A
  • APLM N/A
  • EPS
  • CMND N/A
  • APLM N/A
  • Revenue
  • CMND N/A
  • APLM $198,000.00
  • Revenue This Year
  • CMND N/A
  • APLM $415.15
  • Revenue Next Year
  • CMND N/A
  • APLM N/A
  • P/E Ratio
  • CMND N/A
  • APLM N/A
  • Revenue Growth
  • CMND N/A
  • APLM N/A
  • 52 Week Low
  • CMND $0.80
  • APLM $3.66
  • 52 Week High
  • CMND $2.18
  • APLM $35.98
  • Technical
  • Relative Strength Index (RSI)
  • CMND 52.26
  • APLM 63.91
  • Support Level
  • CMND $0.99
  • APLM $3.66
  • Resistance Level
  • CMND $1.07
  • APLM $6.37
  • Average True Range (ATR)
  • CMND 0.04
  • APLM 0.63
  • MACD
  • CMND 0.00
  • APLM 0.21
  • Stochastic Oscillator
  • CMND 44.44
  • APLM 99.40

About CMND Clearmind Medicine Inc.

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

About APLM Apollomics Inc.

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

Share on Social Networks: